Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313147584> ?p ?o ?g. }
Showing items 1 to 93 of
93
with 100 items per page.
- W4313147584 abstract "<h3>Introduction/Background</h3> In ARIEL3 (NCT01968213), progression-free survival (PFS) improved significantly with rucaparib maintenance treatment versus placebo. We present updated PFS2 and preplanned final overall survival (OS) analyses. <h3>Methodology</h3> ARIEL3 enrolled patients with platinum-sensitive, high-grade ovarian carcinoma who had received ≥2 previous platinum-based chemotherapy regimens and had responded to their last platinum-based regimen. Patients were randomised 2:1 to receive rucaparib 600 mg twice daily or placebo, with 3 protocol-defined nested cohorts: BRCA-mutant, homologous recombination deficient (HRD) and intent-to-treat (ITT). Efficacy outcomes for the nested cohorts included the secondary endpoint of OS (with analysis planned after 70% of events) and the exploratory endpoint of PFS2 (defined as time from randomisation to second event of investigator-assessed disease progression or death due to any cause). Patients were followed for the incidence of myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML). Data cutoff dates were 31 December 2019 (safety), 4 April 2022 (efficacy) and 12 April 2022 (monitoring of MDS/AML). <h3>Results</h3> After a median follow-up of 77.0 months in the ITT population, 410/564 (72.7%) of OS events had occurred. OS and PFS2 are presented in table 1. A PARP inhibitor was administered as subsequent treatment to ≈45% of patients who received placebo. Safety data were consistent with those of prior reports. MDS/AML was reported in 14 (3.8%) and 6 (3.2%) patients in the rucaparib and placebo arms, respectively (<i>P=</i>0.72). Among these, 8 patients in the rucaparib arm and 6 in the placebo arm developed MDS/AML after completion of study drug treatment. <h3>Conclusion</h3> These data support the use of rucaparib as a maintenance treatment for recurrent ovarian carcinoma. Although no OS benefit was observed, the PFS benefit for rucaparib was maintained through the next subsequent line of therapy." @default.
- W4313147584 created "2023-01-06" @default.
- W4313147584 creator A5009234043 @default.
- W4313147584 creator A5018801649 @default.
- W4313147584 creator A5021359849 @default.
- W4313147584 creator A5025155327 @default.
- W4313147584 creator A5026048739 @default.
- W4313147584 creator A5032801379 @default.
- W4313147584 creator A5032881252 @default.
- W4313147584 creator A5051505642 @default.
- W4313147584 creator A5052709676 @default.
- W4313147584 creator A5054602117 @default.
- W4313147584 creator A5056423529 @default.
- W4313147584 creator A5061939825 @default.
- W4313147584 creator A5063407035 @default.
- W4313147584 creator A5064757320 @default.
- W4313147584 creator A5066888430 @default.
- W4313147584 creator A5067053417 @default.
- W4313147584 creator A5072712459 @default.
- W4313147584 creator A5079383798 @default.
- W4313147584 creator A5082234321 @default.
- W4313147584 date "2022-10-01" @default.
- W4313147584 modified "2023-10-17" @default.
- W4313147584 title "2022-RA-249-ESGO Overall survival results from ariel3: a phase 3 randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma" @default.
- W4313147584 doi "https://doi.org/10.1136/ijgc-2022-esgo.488" @default.
- W4313147584 hasPublicationYear "2022" @default.
- W4313147584 type Work @default.
- W4313147584 citedByCount "4" @default.
- W4313147584 countsByYear W43131475842022 @default.
- W4313147584 countsByYear W43131475842023 @default.
- W4313147584 crossrefType "proceedings-article" @default.
- W4313147584 hasAuthorship W4313147584A5009234043 @default.
- W4313147584 hasAuthorship W4313147584A5018801649 @default.
- W4313147584 hasAuthorship W4313147584A5021359849 @default.
- W4313147584 hasAuthorship W4313147584A5025155327 @default.
- W4313147584 hasAuthorship W4313147584A5026048739 @default.
- W4313147584 hasAuthorship W4313147584A5032801379 @default.
- W4313147584 hasAuthorship W4313147584A5032881252 @default.
- W4313147584 hasAuthorship W4313147584A5051505642 @default.
- W4313147584 hasAuthorship W4313147584A5052709676 @default.
- W4313147584 hasAuthorship W4313147584A5054602117 @default.
- W4313147584 hasAuthorship W4313147584A5056423529 @default.
- W4313147584 hasAuthorship W4313147584A5061939825 @default.
- W4313147584 hasAuthorship W4313147584A5063407035 @default.
- W4313147584 hasAuthorship W4313147584A5064757320 @default.
- W4313147584 hasAuthorship W4313147584A5066888430 @default.
- W4313147584 hasAuthorship W4313147584A5067053417 @default.
- W4313147584 hasAuthorship W4313147584A5072712459 @default.
- W4313147584 hasAuthorship W4313147584A5079383798 @default.
- W4313147584 hasAuthorship W4313147584A5082234321 @default.
- W4313147584 hasBestOaLocation W43131475841 @default.
- W4313147584 hasConcept C126322002 @default.
- W4313147584 hasConcept C142724271 @default.
- W4313147584 hasConcept C143998085 @default.
- W4313147584 hasConcept C203092338 @default.
- W4313147584 hasConcept C204787440 @default.
- W4313147584 hasConcept C27081682 @default.
- W4313147584 hasConcept C2776694085 @default.
- W4313147584 hasConcept C2778336483 @default.
- W4313147584 hasConcept C2781413609 @default.
- W4313147584 hasConcept C2908647359 @default.
- W4313147584 hasConcept C535046627 @default.
- W4313147584 hasConcept C71924100 @default.
- W4313147584 hasConcept C99454951 @default.
- W4313147584 hasConceptScore W4313147584C126322002 @default.
- W4313147584 hasConceptScore W4313147584C142724271 @default.
- W4313147584 hasConceptScore W4313147584C143998085 @default.
- W4313147584 hasConceptScore W4313147584C203092338 @default.
- W4313147584 hasConceptScore W4313147584C204787440 @default.
- W4313147584 hasConceptScore W4313147584C27081682 @default.
- W4313147584 hasConceptScore W4313147584C2776694085 @default.
- W4313147584 hasConceptScore W4313147584C2778336483 @default.
- W4313147584 hasConceptScore W4313147584C2781413609 @default.
- W4313147584 hasConceptScore W4313147584C2908647359 @default.
- W4313147584 hasConceptScore W4313147584C535046627 @default.
- W4313147584 hasConceptScore W4313147584C71924100 @default.
- W4313147584 hasConceptScore W4313147584C99454951 @default.
- W4313147584 hasLocation W43131475841 @default.
- W4313147584 hasOpenAccess W4313147584 @default.
- W4313147584 hasPrimaryLocation W43131475841 @default.
- W4313147584 hasRelatedWork W1984282923 @default.
- W4313147584 hasRelatedWork W2091720821 @default.
- W4313147584 hasRelatedWork W2373226427 @default.
- W4313147584 hasRelatedWork W2387456186 @default.
- W4313147584 hasRelatedWork W2388730008 @default.
- W4313147584 hasRelatedWork W2557131790 @default.
- W4313147584 hasRelatedWork W3106263696 @default.
- W4313147584 hasRelatedWork W3200621203 @default.
- W4313147584 hasRelatedWork W4220675698 @default.
- W4313147584 hasRelatedWork W757206253 @default.
- W4313147584 isParatext "false" @default.
- W4313147584 isRetracted "false" @default.
- W4313147584 workType "article" @default.